Skip to main content
. 2019 Sep 12;16(9):e1002901. doi: 10.1371/journal.pmed.1002901

Fig 3. Measures of rheumatoid arthritis disease activity.

Fig 3

Measures of rheumatoid arthritis disease activity at baseline (T0) and after 3 (T3) and 6 months (T6) of treatment with anakinra or TNFi. (A) DAS28. T0: anakinra group (5.42 ± 1.18) versus TNFi group (5.70 ± 0.80); T3: anakinra group (2.95 ± 1.58) versus TNFi group (3.94 ± 1.01), p = 0.039, T6: anakinra group (2.70 ± 1.16) versus TNFi group (3.58 ± 1.45), p = 0.08. (B) SDAI. T0: anakinra group (34.98 ± 25.18) versus TNFi group (35.86 ± 3.47); T3: anakinra group (17.70 ± 10.53) versus TNFi group (18.69 ± 29.55), p = 0. 90; T6: anakinra group (7.89 ± 9.23) versus TNFi group (14.93 ± 9.92), p = 0.0048. (C) PGA. T0: anakinra group (61.90 ± 19.17) versus TNFi group (62.00 ± 17.81); T3: anakinra group (22.21 ± 21.86) versus TNFi group (30.13 ± 19.66), p = 0.27; T6: anakinra group (18.53 ± 23.53) versus TNFi group (25.97 ± 19.99), p = 0.45. (D) VAS of pain. T0: anakinra group (66.86 ± 29.46) versus TNFi group (68.94 ± 22.86); T3: anakinra group (35.37 ± 23.74) versus TNFi group: (44.00 ± 21.98), p = 0.28; T6: anakinra group (27.47 ± 21.67) versus TNFi group (26.46 ± 28.38), p = 0.24. DAS28, Disease Activity Score-28; PGA, physician global assessment; SDAI, simplified disease activity index; TNFi, tumour necrosis factor inhibitor; VAS, visual analogue scale.